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Abstract
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically dis-
play myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of TSC1/2 (Tuberous
Sclerosis 1 and 2) is believed to be a key oncogenic driver in this disease. Recently, a subgroup of PEComas har-
boring TFE3 (Transcription Factor E3) rearrangements and presenting with a distinctive morphology has been
identified. TSC1/2 and TFE3 aberrations are deemed to be mutually exclusive in PEComa, with two different
pathogenic mechanisms assumed to lead to tumorigenesis. Here, we challenge this dichotomy by presenting a
case of a clinically aggressive TCS1-mutated PEComa displaying a TFE3-altered phenotype. FISH analysis was
suggestive of a TFE3 inversion; however, RNA and whole genome sequencing was ultimately unable to identify a
fusion involving the gene. However, a copy number increase of the chromosomal region encompassing TFE3 was
detected and transcriptome analysis confirmed upregulation of TFE3, which was also seen at the protein level.
Therefore, we believe that the TSC1/2-mTOR pathway and TFE3 overexpression can simultaneously contribute to
tumorigenesis in PEComa. Our comprehensive genetic analyses add to the understanding of the complex patho-
genic mechanisms underlying PEComa and harbor insights for clinical treatment options.
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Introduction
PEComas are a family of mesenchymal tumors that
demonstrate immunoreactivity for both melanocytic
and smooth muscle markers [1,2]. They form a bio-
logical continuum ranging from benign to overtly
malignant aggressive neoplasms. Malignant
PEComas are exceedingly rare, with only about
100 cases described in the literature. Radical re-
section remains the favored treatment option in local-
ized tumors. In locally advanced or metastatic
disease, single case studies report short-lived
responses to chemotherapy containing doxorubicin,
ifosfamide or gemcitabine [3].
Germline or somatic mutations of the genes TSC1
or TSC2 (TSC1/2) are a driving factor in PEComa
development, resulting in activation of the mammalian
target of rapamycin (mTOR) pathway [4,5]. These
alterations are the basis for palliative therapy with
mTOR inhibitors [3].
A subset of PEComas harboring TFE3 gene fusions
has recently been identified, adding them to the group
of Xp11 translocation cancers. Here, the introduction
of a constitutively active promotor causes oncogenic
upregulation of the TFE3 transcription factor [6,7].
Beside Xp11 translocations, several other causative
genomic alterations for TFE3 activation likely
exist [8].
Current consensus is that TFE3 and TSC1/2
alterations define distinct biological PEComa sub-
groups and are mutually exclusive [6,9,10]. Here, we
report for the first time a malignant PEComa with
TFE3 activation and heterozygous loss of TSC1. This




Analyses were performed on tumor samples obtained
from a 47-year-old woman diagnosed with PEComa in
2017. Written informed consent for the analyses was
provided by the patient and posthumously by her hus-
band according to local ethical guidelines.
Immunohistochemical staining and fluorescence in
situ hybridization
Samples of the primary tumor and metastases were
formalin-fixed and paraffin-embedded. H&E sta-
ined slides were evaluated by specialized
pathologists at Charité-Universitätsmedizin Berlin
and the reference center for urogenital and soft tis-
sue pathology at the Institute of Pathology of the
University Erlangen-Nürnberg in Erlangen, Ger-
many. Immunohistochemistry was performed as
described in Supplementary materials and methods
using antibodies listed in supplementary material,
Table S1.
Molecular analyses
Quantitative PCR, targeted exome sequencing,
RNA sequencing (RNA-Seq) and nanopore long-
read whole-genome sequencing was performed




In 2017, a 47-year-old woman with known tuberous
sclerosis complex (TSC) due to a heterozygous
germline TSC1 deletion presented with abdominal
pain. A CT scan revealed a mass in the right kidney,
leading to the clinical diagnosis of angiomyolipoma.
Everolimus was initiated at a low dose of 2.5 mg once
daily in accordance with the patient’s wishes, resulting
in trough levels of 2.5–4 ng/ml.
Four months later, imaging showed rapid growth of
the mass. With suspicion of renal cell carcinoma, a
radical nephrectomy was performed. Histopathological
examination led to the diagnosis of a PEComa, which
was 120 × 110 × 110 mm in size and resected to R0.
A CT scan of the lungs showed no pulmonary metas-
tases and the tumor board recommended no adjuvant
therapy.
Four months later, recurrence was seen in a follow-
up CT scan in the region T12-L4. The patient reported
no symptoms at this time. Everolimus was re-initiated
at 5 mg twice daily. In addition, sorafenib was admin-
istered at 200 mg twice daily but had to be discon-
tinued after 2 months due to intolerable
gastrointestinal side effects. The patient also received
radiation therapy of the painful paravertebral mass
(39–45.5 Gy), leading to pronounced tumor
regression.
However, hepatic masses appeared after 12 weeks
and histopathology confirmed the diagnosis of meta-
static malignant PEComa. The patient underwent sur-
gery with R1 resection and did not return to our clinic
for 4 months. By then, multiple hepatic, osseous and
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pulmonary metastases had developed. Chemotherapy
with doxorubicin (75 mg/m2) could only be adminis-
tered once and the patient died of the disease in 2018.
Distinctive TFE3-rearranged phenotype in a TSC1-
altered PEComa
Histomorphologically, conventional PEComas
(so called epithelioid angiomyolipomas) display a
monophasic pattern of predominantly epithelioid cells
and lack adipose tissue and dysmorphic blood vessels
[11]. TFE3-rearranged PEComas show epithelioid
cells arranged into a distinctive nested and
pseudoalveolar pattern [6,10]. The PEComa presented
here matched the latter description, displaying a solid,
partially nested-alveolar architecture with extensive
tumor necrosis as well as hemorrhage. Adipose tissue
and spindle cells were completely absent. The tumor
cells contained voluminous, eosinophilic and partially
clear cytoplasm with prominent nucleoli and
pleomorphic nuclei. Marked nuclear atypia was pre-
sent (Figure 1A).
Immunohistochemical examination of the vital
tumor cells revealed partial patchy expression of
HMB45, focal expression of Melan A and weak posi-
tivity for Cathepsin K, which was mirrored at the
RNA level (see supplementary material, Figure S1).
There was no immunoreactivity for PAX8, smooth
muscle actin and desmin and strong nuclear positivity
for TFE3 was observed, again matching the phenotype
of TFE3-altered PEComas (Figure 1B) [6,10]. As
opposed to the primary tumor, MiTF positivity was
seen in hepatic metastases (Figure 1C,D), while pul-
monary metastases displayed only weak MiTF mRNA
expression (see supplementary material, Figure S1).
Many TFE3-rearranged PEComas are MiTF-
nonimmunoreactive and it has been suggested that the
TFE3 fusion protein substitutes for MiTF [6]. We con-
sider tumor heterogeneity a possible explanation for
the differential MiTF expression, with perhaps only a
subset of tumor cells exhibiting TFE3 activation.
Figure 1. PEComa histology and immunohistochemistry (IHC). (A) Representative image of the histomorphological appearance of the
presented case (100-fold total magnification, H&E staining). (B) TFE3 expression in tumor cells (200-fold total magnification). (C) No
MiTF expression in tumor cells from primary tumor (200-fold total magnification). (D) MiTF expression in tumor cells from hepatic
metastasis (200-fold total magnification).
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Evidence for a dual pathogenic mechanism
involving TFE3 and TSC1 in our PEComa case
The known heterozygous germline TSC1 deletion was
verified by real-time PCR (see supplementary material,
Figure S2) and only residual TSC1 expression was
seen in the transcriptome (see supplementary material,
Figure S1). The tumor morphology and TFE3 immu-
noreactivity, however, were suggestive of a TFE3
fusion. Therefore, fluorescence in situ hybridization
(FISH) analysis was performed on the primary tumor.
Out of 50 tumor cells, only three showed a trans-
located break-apart signal (Figure 2A). The other
examined cells did not meet the break-apart cutoff
values, but several cells displayed one co-localization
signal and one small separation of the 50TFE3 and
30TFE3 probes (Figure 2B). Similar subtle break-apart
patterns have been described in tumors harboring
TFE3 inversions rather than translocations [12,13,14].
However, RNA-Seq analysis performed on a pulmo-
nary PEComa lesion was unable to identify any gene
fusions involving TFE3. In order to find aberrations
missed by RNA-Seq, we next performed long-read
whole genome sequencing. Structural variant calling
also did not detect TFE3 fusions. However, multiple
copy number gains were found, including a large
36 Mbp region encompassing TFE3 on
chrX:22015149-58073962 (Figures 3 and 4). Trans-
criptome analysis detected an increase in levels of
TFE3 mRNA in tumor cells compared to dermal fibro-
blast controls after normalization for expression of
housekeeping genes (see supplementary material,
Figure S1). Therefore, similar to Xp11 translocation
cancers, TFE3 overexpression is one likely oncogenic
driver in this tumor [15].
In addition, targeted exome sequencing revealed a
coexistent TP53 mutation. The variant NM_000546.5:
c.614A>G (p.Y205C) found was classified as
Figure 2. Interphase FISH with TFE3 break-apart probe. (A) Break-apart signal as seen in 6% of cells (arrow). (B) Small separation of the
TFE3 probes (arrow).
Figure 3. Genomic profiling by an Oxford Nanopore Sequencing-based assay of PEComa chromosomes 1-22 finds multiple copy number
variations. 2-Fold genome coverage was achieved; counts averaged over 0.5 MB. Chromosome X is not analyzed or depicted here due to
the algorithm used.
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pathogenic. TP53 mutations do occur concurrently
with TSC1/2 mutations [10] but have not been
described in TFE3-altered PEComas until now. No
additional pathogenic mutations were detected in the
other genes tested in our panel (see supplementary
material, Table S2).
Conclusion and clinical remarks
In the case presented here, it is clear that the heterozy-
gous loss of TSC1 predisposed to PEComa develop-
ment, but we believe that the sequential gain of TFE3
contributed to tumorigenesis. Interestingly, the
observed TFE3 activation was not due to a TFE3 gene
fusion, analogous to reports on TFE3-expressing/non-
translocated renal cell carcinomas. These tumors are
hypothesized to share a biological mechanism with
their translocated counterparts based on a similar mor-
phology, immunolabeling and increased expression of
a common RNA read-through molecule [16,17]. In
some of these neoplasms, TFE3 amplification leads to
increased gene expression, but other mechanisms
resulting in elevated TFE3 levels likely also exist
[8,18]. The same presumably holds true for PEComas
like the one presented here. Regarding the TFE3
expression in our case, clonal tumor evolution appears
to have played an additional role during the course of
disease. At initial diagnosis, FISH analysis was unable
to detect a TFE3 amplification in the primary tumor,
although genomic profiling of metastases later rev-
ealed a copy number gain. Perhaps the additional
TP53 mutation, which presumably also contributed to
the complex karyotypic changes, promoted the selec-
tion of a TFE3-expressing PEComa subclone in which
genomic material on chromosome X was consecu-
tively gained. Indeed, the differential MiTF expression
observed here suggests tumor heterogeneity and sup-
ports our hypothesis of clonal tumor evolution.
To our knowledge, this is the first case with con-
firmed heterozygous deletion in a TSC gene and con-
comitant TFE3 activation with a distinctive malignant
epithelioid phenotype. This finding challenges the
Figure 4. Genomic profiling by an Oxford Nanopore Sequencing-based assay of PEComa chromosome X finds copy number gain at
chrX:22015149-58073962. 2-Fold genome coverage was achieved. Copy number variation for chromosome X (top left panel) and
enlarged view of copy number changes for TFE3 (lower right panel).
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biological distinction of TFE3- and TCS1/2-altered
PEComas. The notion that both the TSC1/2-mTOR
pathway and TFE3 overexpression can simultaneously
contribute to tumorigenesis in PEComa is of transla-
tional clinical importance. TSC1/2-mutated PEComas
sometimes respond to mTOR-inhibition therapy [19],
but these drugs are mechanistically believed to be inef-
ficient in TFE3-altered PEComa. MET-inhibitors, on
the other hand, are active in alveolar soft part sarcoma
with TFE3 rearrangement [20], a rare subtype of soft-
tissue sarcoma, and could constitute a therapeutic
option for TFE3 overexpressing PEComas. Impor-
tantly, when there is evidence of dual pathway activa-
tion, it appears reasonable to combine both drugs.
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